Design Therapeutics (Design Therapeutics) FCF Yield % : -27.54 (As of Apr. 27, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Design Therapeutics's Trailing 12-Month Free Cash Flow is $-58.82 Mil, and Market Cap is $213.55 Mil. Therefore, Design Therapeutics's FCF Yield % for today is -27.54%.

The historical rank and industry rank for Design Therapeutics's FCF Yield % or its related term are showing as below:

DSGN' s FCF Yield % Range Over the Past 10 Years
Min: -55.3 Med: 0 Max: 0
Current: -27.54

DSGN's FCF Yield % is ranked worse than
63.81% of 1550 companies
in the Biotechnology industry
Industry Median: -15.535 vs DSGN: -27.54

Design Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Design Therapeutics FCF Yield % Historical Data

The historical data trend for Design Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Design Therapeutics FCF Yield % Chart

Design Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-2.60

-9.11

-39.30

Design Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial												-10.73	-21.71	-15.76	-44.15	-34.28

Competitive Comparison of Design Therapeutics's FCF Yield %

For the Biotechnology subindustry, Design Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Design Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's FCF Yield % falls into.

Design Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Design Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-58.816	/	149.65504
	=	-39.30%

Design Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-12.825	*	4	/	149.65504
	=	-34.28%

Design Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Design Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Design Therapeutics (Design Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011

Website

https://www.designtx.com

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

Executives

Rodney W Lappe	director	C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Deepa Prasad	director	C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Arsani William	director	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Joao Md Siffert	director, officer: President and CEO	20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George	director, 10 percent owner	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu	director, 10 percent owner	C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess	officer: Chief Accounting Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio	officer: Principal Accounting Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Pratik Shah	director, officer: Executive Chairperson	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Sean Jeffries	officer: Chief Operating Officer	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker	officer: Vice President, Finance	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Aseem Z. Ansari	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011